ClinicalTrials.gg
RecruitingNCT06553053Updated Apr 13, 2026

Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial

An interventional study of "Harmonizing Shaoyang, nourishing spleen and kidney with warmth" Acupuncture Group and "Nourishing spleen and kidney with warmth" Acupuncture Group in Crohn's Disease Relapse and Inflammatory Bowel Diseases, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Recruiting at 1 site in China. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Planned enrollment
23rd of 60
106 · median 97
Started
2024
with 11 others
No phase
28 of 114
16 open now
Primary completion
2028-12
later than 48 of 54 live
Registered
68th of 114
by date
Lead sponsor
4 of 114
Shanghai Institute of Acupuncture, Moxibustion and Meridian

Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 23rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 12 that started in 2024, is one of 28 with no phase, reaches primary completion later than 48 of the 54 other live ones, and was the 68th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.

Read the detailed description

Acupuncture has been proven to be an effective and safe treatment for CD. In this trial, based on previous studies, which mainly treated CD from the perspective of spleen and stomach tonification, we explored the therapeutic effect of acupuncture in treating CD from the perspective of tonifying the Shaoyang pivot mechanism to enhance the therapeutic effect.Brain-gut axis dysfunction is one of the important pathogenic mechanisms of CD. This trial attempted to explore the therapeutic targets and efficacy mechanisms of acupuncture to enhance CD by analysing brain-gut axis multi-pathway indicators.

03

Conditions studied

  • Crohn's Disease Relapse
  • Inflammatory Bowel Diseases
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients with clinical diagnosis consistent with CD;
  2. aged 16-75;
  3. patients in remission (CDAI \< 150 and CRP \< 5mg/l, or Faecal calprotectin \< 50μg/g, or no ulcer under endoscopy);
  4. patients with frequent disease recurrences (≥2) in the past years;
  5. patients were not taking medication or were only taking one or more of the following drugs: [mesalazine (≤4g/d), prednisone (≤15mg/d), azathioprine (≤1mg/kg/d)] and prednisone and mesalazine were used for at least 1 month, while azathioprine was used for at least 3 months; or those who had poor response or loss of response to biological preparations (anti-TNF-α, IL-12p40, α4β7);
  6. those who have never experienced acupuncture;
  7. patients signing .

Exclusion criteria

Exclusion Criteria:

  1. patients who are recently pregnant or in pregnancy or lactation;
  2. patients with serious organic diseases;
  3. patients diagnosed as psychosis;
  4. patients who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;
  5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;
  6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;
  7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;
  8. there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Receiving acupuncture with the function of "harmonizing Shaoyang, nourishing spleen and kidney with warmth"

    Other: "Harmonizing Shaoyang, nourishing spleen and kidney with warmth" Acupuncture Group

  • Active comparator
    Control group

    Receiving acupuncture group with the function of "nourishing spleen and kidney with warmth"

    Other: "Nourishing spleen and kidney with warmth" Acupuncture Group

Interventions

  • Other"Harmonizing Shaoyang, nourishing spleen and kidney with warmth" Acupuncture Group

    Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.

  • Other"Nourishing spleen and kidney with warmth" Acupuncture Group

    Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.

06

What researchers measure

Primary outcomes

  1. The proportion of recurrences

    Defined as CDAI \> 150 and increase ≥ 70 points, or emergency, hospitalization and surgical events due to worsening of CD conditions, or need to adjust drug to control disease condition.

    Time frame: Week 52

Secondary outcomes

  1. Number of recurrences

    Total number of recurrences. The median number will be counted for both groups.

    Time frame: Week 52

  2. Time of recurrences

    Time to first recurrence will be counted for both groups.

    Time frame: Week 52

  3. Crohn's disease activity index (CDAI)score

    The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.

    Time frame: Week 0, 6, 12, 24, 36 and 52

  4. Patient Reported Outcome (PRO2)

    The outcome is measured by level of abdominal pain (visual analogue scale, VAS) and number of diarrhoea in the past week.

    Time frame: Week 0, 6, 12, 24, 36 and 52

  5. First laboratory tests

    serum C-reactive protein (CRP)

    Time frame: Week 0, 6, 12, 24, 36 and 52

  6. Second laboratory tests

    erythrocyte sedimentation rate (ESR)

    Time frame: Week 0, 6, 12, 24, 36 and 52

  7. Third laboratory tests

    platelet count (PLT)

    Time frame: Week 0, 6, 12, 24, 36 and 52

  8. Inflammatory bowel disease questionnaire (IBDQ)

    The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.

    Time frame: Week 0, 12, 24, 36 and 52

  9. Hospital anxiety and depression scale (HADS)

    The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.

    Time frame: Week 0, 12, 24, 36 and 52

  10. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)

    The mean change in FACIT-F from baseline. The higher the score, the worse the condition. The score range from 0 to 52.

    Time frame: Week 0, 12, 24, 36 and 52

  11. Colonoscopy or small bowel MR evaluation

    measured by colonoscopy (SES-CD score) or small bowel MR (MaRIA score)

    Time frame: Week 0 and 52

  12. Expectation of acupuncture treatment

    measured by acupuncture treatment effectiveness expectation questionnaire

    Time frame: Week 0

  13. Blind questionnaire

    measured by patients guessing their grouping

    Time frame: Week 6 and 12

Other outcomes

  1. Effects of acupuncture on brain network connectivity properties

    Gray matter structure of the brain,functional connectivity and network properties of brain networks and local activity in brain regions were measured in an attempt to analyze the correlation between changes in these indicators after acupuncture intervention and the efficacy of acupuncture.

    Time frame: Week 0 and 12

  2. Salivary cortisol

    Salivary cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.

    Time frame: Week 0 and 12

  3. α-Salivary Amylase

    α-Salivary Amylase is measured by ELISA to analyze effect of acupuncture on HPA axis function.

    Time frame: Week 0 and 12

  4. Serum cortisol

    Serum cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.

    Time frame: Week 0 and 12

  5. Effect of acupuncture on autonomic nervous activity

    The effect of acupuncture on autonomic function was recorded by DMS300-4AL.

    Time frame: Week 0 and 12

  6. Effect of acupuncture on intestinal inflammation levels function

    Intestinal inflammation levels are measured by C-reactive protein and plasma concentrations of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6.

    Time frame: Week 0 and 12

  7. Effect of acupuncture on intestinal mucosal barrier function

    Intestinal mucosal barrier function are measured by concentrations of lipopolysaccharide (LPS), Diamine oxidase (DAO) and D-lactate.

    Time frame: Week 0 and 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dolinger M, Torres J, Vermeire S. Crohn's disease. Lancet. 2024 Mar 23;403(10432):1177-1191. doi: 10.1016/S0140-6736(23)02586-2. Epub 2024 Mar 1. PubMed 38437854 ↗
  • Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease. Nat Rev Dis Primers. 2020 Apr 2;6(1):22. doi: 10.1038/s41572-020-0156-2. PubMed 32242028 ↗
  • Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):307-317. doi: 10.1080/17474124.2019.1574569. Epub 2019 Feb 20. PubMed 30791773 ↗
  • Ng SC, Leung WK, Shi HY, Li MK, Leung CM, Ng CK, Lo FH, Hui YT, Tsang SW, Chan YK, Loo CK, Chan KH, Hui AJ, Chow WH, Harbord M, Ching JY, Lee M, Chan V, Tang W, Hung IF, Ho J, Lao WC, Wong MT, Sze SF, Shan EH, Lam BC, Tong RW, Mak LY, Wong SH, Wu JC, Chan FK, Sung JJ. Epidemiology of Inflammatory Bowel Disease from 1981 to 2014: Results from a Territory-Wide Population-Based Registry in Hong Kong. Inflamm Bowel Dis. 2016 Aug;22(8):1954-60. doi: 10.1097/MIB.0000000000000846. PubMed 27416041 ↗
  • Zheng JJ, Zhu XS, Huangfu Z, Gao ZX, Guo ZR, Wang Z. Crohn's disease in mainland China: a systematic analysis of 50 years of research. Chin J Dig Dis. 2005;6(4):175-81. doi: 10.1111/j.1443-9573.2005.00227.x. PubMed 16246226 ↗
  • Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150. Epub 2015 Sep 1. PubMed 26323879 ↗
  • Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14. PubMed 27189910 ↗
  • Esters P, Dignass A. Complementary therapies in inflammatory bowel diseases. Curr Drug Targets. 2014;15(11):1079-88. doi: 10.2174/1389450115666140903112802. PubMed 25182607 ↗
  • Qu YK, Zhu Y.Differential diagnosis and treatment of Crohn's disease based on the theory of
  • Bao C, Wu L, Wang D, Chen L, Jin X, Shi Y, Li G, Zhang J, Zeng X, Chen J, Liu H, Wu H. Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial. EClinicalMedicine. 2022 Feb 12;45:101300. doi: 10.1016/j.eclinm.2022.101300. eCollection 2022 Mar. PubMed 35198926 ↗
  • Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology. 2018 May;154(6):1635-1646.e3. doi: 10.1053/j.gastro.2018.01.027. Epub 2018 Jan 31. PubMed 29366841 ↗
  • Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):632-642. doi: 10.1016/S2468-1253(19)30089-5. Epub 2019 May 20. PubMed 31122802 ↗
  • Fairbrass KM, Lovatt J, Barberio B, Yuan Y, Gracie DJ, Ford AC. Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut. 2022 Sep;71(9):1773-1780. doi: 10.1136/gutjnl-2021-325985. Epub 2021 Nov 1. PubMed 34725197 ↗
  • Pellissier S, Dantzer C, Mondillon L, Trocme C, Gauchez AS, Ducros V, Mathieu N, Toussaint B, Fournier A, Canini F, Bonaz B. Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One. 2014 Sep 10;9(9):e105328. doi: 10.1371/journal.pone.0105328. eCollection 2014. PubMed 25207649 ↗
  • Bonaz B, Sinniger V, Hoffmann D, Clarencon D, Mathieu N, Dantzer C, Vercueil L, Picq C, Trocme C, Faure P, Cracowski JL, Pellissier S. Chronic vagus nerve stimulation in Crohn's disease: a 6-month follow-up pilot study. Neurogastroenterol Motil. 2016 Jun;28(6):948-53. doi: 10.1111/nmo.12792. Epub 2016 Feb 27. PubMed 26920654 ↗
  • Tillisch K, Labus JS. Advances in imaging the brain-gut axis: functional gastrointestinal disorders. Gastroenterology. 2011 Feb;140(2):407-411.e1. doi: 10.1053/j.gastro.2010.12.014. Epub 2010 Dec 15. No abstract available. PubMed 21167161 ↗
  • Stasi C, Orlandelli E. Role of the brain-gut axis in the pathophysiology of Crohn's disease. Dig Dis. 2008;26(2):156-66. doi: 10.1159/000116774. Epub 2008 Apr 21. PubMed 18431066 ↗
  • del Rey A, Klusman I, Besedovsky HO. Cytokines mediate protective stimulation of glucocorticoid output during autoimmunity: involvement of IL-1. Am J Physiol. 1998 Oct;275(4):R1146-51. doi: 10.1152/ajpregu.1998.275.4.R1146. PubMed 9756545 ↗
  • Mackner LM, Clough-Paabo E, Pajer K, Lourie A, Crandall WV. Psychoneuroimmunologic factors in inflammatory bowel disease. Inflamm Bowel Dis. 2011 Mar;17(3):849-57. doi: 10.1002/ibd.21430. Epub 2010 Aug 18. PubMed 20722061 ↗
  • Wang L, Bai AP. Dysfunction of the autonomic nervous system and inflammatory bowel disease.World Chinese Journal of Digestology 2012;[20]20: 3010-3014.
  • Pellissier S, Dantzer C, Canini F, Mathieu N, Bonaz B. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. Psychoneuroendocrinology. 2010 Jun;35(5):653-62. doi: 10.1016/j.psyneuen.2009.10.004. Epub 2009 Nov 11. PubMed 19910123 ↗
  • Prame Kumar K, Ooi JD, Goldberg R. The interplay between the microbiota, diet and T regulatory cells in the preservation of the gut barrier in inflammatory bowel disease. Front Microbiol. 2023 Dec 1;14:1291724. doi: 10.3389/fmicb.2023.1291724. eCollection 2023. PubMed 38107848 ↗
  • Bao CH, Liu P, Liu HR, Wu LY, Shi Y, Chen WF, Qin W, Lu Y, Zhang JY, Jin XM, Wang XM, Zhao JM, Liu XM, Tian J, Wu HG. Alterations in brain grey matter structures in patients with crohn's disease and their correlation with psychological distress. J Crohns Colitis. 2015 Jul;9(7):532-40. doi: 10.1093/ecco-jcc/jjv057. Epub 2015 Apr 20. PubMed 25895879 ↗
  • Bao CH, Liu P, Liu HR, Wu LY, Jin XM, Wang SY, Shi Y, Zhang JY, Zeng XQ, Ma LL, Qin W, Zhao JM, Calhoun VD, Tian J, Wu HG. Differences in regional homogeneity between patients with Crohn's disease with and without abdominal pain revealed by resting-state functional magnetic resonance imaging. Pain. 2016 May;157(5):1037-1044. doi: 10.1097/j.pain.0000000000000479. PubMed 26761381 ↗
  • Agostini A, Benuzzi F, Filippini N, Bertani A, Scarcelli A, Farinelli V, Marchetta C, Calabrese C, Rizzello F, Gionchetti P, Ercolani M, Campieri M, Nichelli P. New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. Neurogastroenterol Motil. 2013 Feb;25(2):147-e82. doi: 10.1111/nmo.12017. Epub 2012 Sep 23. PubMed 22998431 ↗
  • Bao CH, Xu S, Wu LY, et al. Brain imaging features predict disease activity in patients with Crohn's disease. Gastroenterology, 2024, 166(5): S-205.
  • Bao CH, Wu LY, Liu HR, et al. Acupuncture reduces clinical relapse in Crohn's disease: a randomized controlled trial. Gastroenterology, 2023, 164(6): S-1093.
  • Chow, S.C., Shao, J., and Wang, H. 2008. Sample Size Calculations in Clinical Research, Second Edition.Chapman & Hall/CRC. Boca Raton, Florida.
  • Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology Chinese Medical Association, Inflammatory Bowel Disease Quality Control Center of China.Chinese clinical practice guideline on the management of Crohn's disease (2023, Guangzhou)[J].Chinese Journal of Inflammatory Bowel Diseases, 2024,8(1):2-32.
  • Albenberg L, Brensinger CM, Wu Q, Gilroy E, Kappelman MD, Sandler RS, Lewis JD. A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares. Gastroenterology. 2019 Jul;157(1):128-136.e5. doi: 10.1053/j.gastro.2019.03.015. Epub 2019 Mar 11. PubMed 30872105 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2028, 52 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 52 months is above that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 14, 2024
StartActual
Aug 13, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06553053
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Collaborators
Ruijin Hospital
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Aug 13, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Bao Chunhui, MD, PhD
Contact
baochunhui789@126.com
+862164395973
Bao Chunhui, MD, PhD
principal investigator · Shanghai University of TCM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion